Cargando…
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pha...
Autores principales: | Sweeting, Arianne N, Tabet, Eddy, Caterson, Ian D, Markovic, Tania P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926768/ https://www.ncbi.nlm.nih.gov/pubmed/24550678 http://dx.doi.org/10.2147/DMSO.S38979 |
Ejemplares similares
-
Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011) -
Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015) -
Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management
por: Garvey, William Timothy
Publicado: (2013) -
Phentermine–topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report
por: Grunvald, Eduardo, et al.
Publicado: (2022) -
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013)